The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around device<a href="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...</a>
Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the<a href="https://solaci.org/en/2024/02/07/should-we-treat-obstructive-coronary-artery-disease-in-tavi/" title="Read more" >...</a>
TAVR can be associated to early valve thrombosis, characterized by thrombi formation near or attached to the prosthetic valve, with or without valve dysfunction. This dysfunction is associated with increased leaf thickening and reduced leaflet motion, as well as reduced orifice area or increased transvalvular gradient. Triggered multislice CT allows dynamic valve assessment and thrombosis<a href="https://solaci.org/en/2024/01/25/use-of-apixaban-and-post-tavr-valve-thrombosis/" title="Read more" >...</a>
Both Acurate Neo2 and its predecessor, Acurate Neo, have proven their safety and efficacy in the percutaneous treatment of severe aortic stenosis. The Acurate platform offers a lower gradient and a larger effective orifice area, as well as a low risk of periprocedural complications, according to previous registries. However, the first-generation Acurate device had some<a href="https://solaci.org/en/2024/01/12/acurate-neo2-one-year-hemodynamic-and-clinical-benefit-results/" title="Read more" >...</a>
Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise. TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>
Discover the most read scientific articles on interventional cardiology of 2022 in our website. No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of<a href="https://solaci.org/en/2023/12/27/interventional-cardiology-the-most-read-articles-of-2023/" title="Read more" >...</a>
TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker. This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>
iFR has been validated as a useful tool for intermediate lesion analysis, with the advantage of not requiring the use of drugs. On the other hand, its use for PCI outcome assessment has not yet been thoroughly looked into, even though there have been promising data. 24% of DEFINE PCI cases presented ≤0.89 iFR with<a href="https://solaci.org/en/2023/12/07/ifr-guided-pci-to-the-lad-same-as-for-non-lad-vessels/" title="Read more" >...</a>
Aortic stenosis (AS) is a progressive disease associated with morbidity and mortality, especially in severe cases. However, recent studies have revealed that moderate stenosis can also have unfavorable consequences in the course of the disease. One of the challenges lies in that determining its severity is sometimes difficult due to discrepancies between valve area, gradient,<a href="https://solaci.org/en/2023/12/04/is-as-only-important-when-severe/" title="Read more" >...</a>
The incidence of stroke after TAVR ranges between 2 and 5%, depending on the series, which has been associated with higher morbimortality, affecting patient quality of life and their psycho-social environment. Many cerebral embolic protection systems have been developed in response, and even though they have been shown beneficial in many studies, their role in<a href="https://solaci.org/en/2023/11/16/captis-a-novel-cerebral-embolic-protection-system-in-tavr/" title="Read more" >...</a>